PVLA Company Profile and Key Details

Palvella Therapeutics, Inc. has 11.06 million shares outstanding. The public float is 6.38 million shares, elevated short interest at 7.73% of float. This equals 701.67 thousand shares. The short ratio is 4.28 days. Institutional investors hold 109.06% of the float. Insiders own 11.65%. JENKINS GEORGE M holds 187.62 thousand shares, HERON ELAINE J has 47.81 thousand shares and Goin Kathleen has 0.00 shares. Over the past six months, insider transactions show net selling. They sold 5.50 thousand shares across 6 transactions.

Palvella Therapeutics, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $5.10. This means the shares are trading above this model’s fair value.

Palvella Therapeutics, Inc. (NASDAQ:PVLA) closed at $146.03 USD, gaining $1.27 (0.88%) from the previous close of $144.76. The stock is currently mid-range between its 52-week high and low $25.80 and $161.38. With a market capitalization of about $1.73 billion, Palvella Therapeutics, Inc. is classified as a small-cap and shows lower-than-market volatility (beta ~-0.19). Key stats such as the average daily volume over the past year has been around 259.46 thousand shares, in line with its 52-week average. Headquartered in Wayne, PA, Palvella Therapeutics, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Wesley H. Kaupinen, the company employs approximately 29 people and listed since January 02, 2015. Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative treatments for patients afflicted with severe and uncommon inherited skin conditions.

Palvella Therapeutics, Inc. generated EPS of $nan over the past year. Five-year average earnings growth is 29.42%. Wall Street analysts project EPS growth of 13.97% annually over the next five years. Analyst sentiment is bullish. Analyst rating data shows there are 9 Strong Buy ratings, 34 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $270.00 to $54.00. The high target offers 84.89% upside. The low target suggests -63.02% downside. The mean target is $155.95. This offers 6.79% upside. Palvella Therapeutics, Inc. earnings surprise history is a mixed track record. The quarter that ended May 07, 2026, missed forecasts by 33.33%. The prior quarter beat by 18.53%. Over the last six quarters, Apple has recorded several small beats. These include -1125.64% in March 31, 2025.

Palvella Therapeutics, Inc. trades at a P/E ratio of -34.95, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 8.21 trading at moderately above to book value. The P/FCF stands at -59.29, also below market averages.

Palvella Therapeutics, Inc. (NASDAQ:PVLA) shares are flat -6.36% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Palvella Therapeutics, Inc. trading at a premium to the broader market with a P/E of -34.95. Analyst sentiment is bullish, with the majority of ratings in Overweight territory and a mean price target of $131.05, suggesting -10.26% downside. Our AI forecast model points to short-term strength (14.33% over two weeks), a medium-term rise (74.22% over three months), and a longer-term gain (68.6% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Palvella Therapeutics, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 14.33%, with price expected at $166.95 by July 27, 2026, within a range of $158.30 to $175.92 3-Month Outlook: Projected rise of 74.22%, reaching $254.41 by October 09, 2026, with a range of $252.28 to $256.54. 1-Year Outlook: Projected gain of 68.6%, with price at $246.20 by July 13, 2027, within a range of $242.12 to $250.55.